ロード中...
Alemtuzumab in allogeneic hematopoetic stem cell transplantation
INTRODUCTION: With the use of reduced-intensity conditioning (RIC), early toxicity of allogeneic stem cell transplantation (SCT) has been much reduced. Graft-versus-host disease (GvHD) causes morbidities and mortality. Alemtuzumab is a mAb directed against CD52. When administered prior to transplant...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3126913/ https://ncbi.nlm.nih.gov/pubmed/21702703 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14712598.2011.592824 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|